 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
109 News |  |
| «12 |
- febuxostat / Generic mfg.
Enrollment closed: Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule (clinicaltrials.gov) - Apr 8, 2015
P1, N=36, Active, not recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting
- | febuxostat / Generic mfg.
New P1 trial: Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule (clinicaltrials.gov) - Mar 9, 2015
P1, N=36, Not yet recruiting, Sponsor: Takeda
- Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda
Clinical: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Azienda Ospedaliera Sant'Anna
- | Aptivus (tipranavir) / Boehringer Ingelheim
New P1 trial: Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers (clinicaltrials.gov) - Sep 22, 2014
P1, N=23, Completed, Sponsor: Boehringer Ingelheim
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=17, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting N=24 --> 17
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=17, Completed, Sponsor: University of Colorado, Denver
N=24 --> 17 Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) - May 18, 2014
P1, N=15, Recruiting, Sponsor: Helen Reynolds
Recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- Isentress (raltegravir) / Merck (MSD)
Trial completion date: The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) - May 18, 2014
P1, N=15, Recruiting, Sponsor: Helen Reynolds
Trial primary completion date: May 2014 --> May 2015 Trial completion date: Dec 2014 --> Dec 2015
- Isentress (raltegravir) / Merck (MSD)
Enrollment open: The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) - May 18, 2014
P1, N=15, Recruiting, Sponsor: Helen Reynolds
Trial completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial initiation date: The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) - May 18, 2014
P1, N=15, Not yet recruiting, Sponsor: Helen Reynolds
Not yet recruiting --> Recruiting Initiation date: Sep 2013 --> Dec 2013
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) (clinicaltrials.gov) - Dec 22, 2013
P1, N=18, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Sep 2013 --> Dec 2013 Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
New P1 trial: A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) (clinicaltrials.gov) - Aug 26, 2013
P1, N=18, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Isentress (raltegravir) / Merck (MSD)
New P1 trial: The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) - Feb 3, 2013
P1, N=15, Not yet recruiting, Sponsor: Helen Reynolds
- Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
Trial completion: The Effects of Moviprep With Simethicone on Colonic Bubbles (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=140, Completed, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Active, not recruiting --> Completed